GLP-1 vs. SGLT2 Inhibitors: Side-by-Side Comparison​

GLP-1 receptor agonists and SGLT2 inhibitors are two medication classes used to manage type 2 diabetes, but they work differently and offer distinct health benefits. GLP-1 medications improve glucose-dependent insulin secretion, regulate appetite, and can produce substantial weight loss.

SGLT2 inhibitors lower blood sugar by helping the kidneys remove excess glucose through urine and have important benefits for heart failure and chronic kidney disease.

GLP-1 medications are often particularly useful when significant weight reduction is a treatment priority. SGLT2 inhibitors may be preferred for eligible patients with heart failure or chronic kidney disease because of their demonstrated benefits in these conditions.

Both medication classes include treatments that reduce cardiovascular risks in specific patient populations. The better treatment depends on the patient’s HbA1c, body weight, cardiovascular health, kidney function, other medical conditions, and medication preferences.

Some patients benefit from taking a GLP-1 receptor agonist and an SGLT2 inhibitor together, sometimes alongside metformin, rather than choosing only one medication class.

DFWPMA offers in-person GLP-1 prescription evaluations in Texas and can prescribe GLP-1 medications at a DFWPMA location across Texas to eligible patients when medically appropriate, subject to medication availability.

Our primary care providers and endocrinologists also offer ongoing care to monitor potential side effects, address health concerns, and support patients throughout GLP-1 treatment. DFWPMA does not currently offer online GLP-1 prescriptions, an in-person evaluation is required.

Book an appointment online or call (903) 957-0082 to contact our scheduling team.

Get Prescriptions for GLP-1 Medications at a DFWPMA Location Near You!

📍 GLP-1 Prescription Providers in Fort Worth, TX

1220 W Presidio St, Fort Worth, TX 76102

Book an Appointment at Our Fort Worth Location →
📍 GLP-1 Prescription Providers in Frisco, TX

7589 Preston Rd., Suite 900, Frisco, TX 75034

Book an Appointment at Our Frisco Location →
📍 GLP-1 Prescription Providers in Sherman, TX

425 N Highland Ave., Suite 260, Sherman, TX 75092

Book an Appointment at Our Sherman Location →
📞 Call DFWPMA to Schedule

Speak with our scheduling team about GLP-1 prescription evaluations, provider availability, and appointments.

Call Us → (903) 957-0082

We accept many major insurance plans. Not sure if your plan is accepted?

Call (903) 957-0082 and our team can help verify coverage.

What Is GLP-1?

GLP-1 (glucagon-like peptide-1) is a naturally occurring hormone that helps regulate blood sugar, insulin secretion, appetite, and digestion. GLP-1 receptor agonists are medications that mimic this hormone to improve blood glucose control and, depending on the medication, support weight management.

Examples include semaglutide (Ozempic and Wegovy), liraglutide (Victoza and Saxenda), and dulaglutide (Trulicity). These medications differ in their approved indications, effectiveness, and dosing schedules. Tirzepatide (Mounjaro and Zepbound) is a related medication that activates both GIP and GLP-1 receptors rather than GLP-1 receptors alone.

When to Use GLP-1 Medications

GLP-1 medications may be prescribed to patients with type 2 diabetes who need improved blood sugar control, particularly when weight reduction is also a treatment priority. Certain GLP-1 medications are also approved for chronic weight management in eligible patients with obesity or overweight, including some individuals without diabetes. Specific GLP-1 medications may provide additional cardiovascular or kidney benefits in qualifying patients.

GLP-1 treatment may be particularly appropriate in the following situations:

  • Type 2 Diabetes: When blood sugar remains above individualized treatment targets or a GLP-1 medication offers additional clinically appropriate benefits.
  • Obesity and Weight Management: When an eligible patient needs substantial, sustained weight reduction and meets the prescribing criteria for an approved medication.
  • Cardiovascular Risk: When a patient meets the indications for a GLP-1 medication with demonstrated cardiovascular protection.
  • Chronic Kidney Disease: When a patient qualifies for a GLP-1 medication with demonstrated kidney-related benefits.
  • Combination Diabetes Treatment: When additional blood sugar control or weight-management benefits are needed alongside metformin or other appropriate diabetes medications.

What Are SGLT2 Inhibitors?

SGLT2 inhibitors (sodium-glucose cotransporter-2 inhibitors) are prescription medications that lower blood sugar by preventing the kidneys from reabsorbing some of the glucose filtered from the bloodstream. This causes excess glucose to leave the body through urine. Certain SGLT2 inhibitors also reduce the risk of heart failure hospitalization and slow chronic kidney disease progression in eligible patients, including some people without diabetes.

Examples include empagliflozin (Jardiance), dapagliflozin (Farxiga), canagliflozin (Invokana), and ertugliflozin (Steglatro). SGLT2 inhibitors are generally taken as once-daily oral tablets. Their approved indications vary by medication and may include type 2 diabetes, heart failure, or chronic kidney disease.

When to Use SGLT2 Inhibitors

SGLT2 inhibitors may be prescribed to patients with type 2 diabetes who need improved blood sugar control, particularly when heart failure or chronic kidney disease is also present. Certain SGLT2 inhibitors are approved to treat eligible patients with heart failure or chronic kidney disease even when they do not have diabetes. These medications may also produce modest weight loss and reductions in blood pressure.

SGLT2 treatment may be particularly appropriate in the following situations:

  • Type 2 Diabetes: When additional glucose-lowering treatment is needed or a patient may benefit from the medication’s cardiovascular or kidney effects.
  • Heart Failure: When a patient qualifies for an SGLT2 inhibitor approved to reduce heart failure hospitalization or other specified cardiovascular risks.
  • Chronic Kidney Disease: When a patient meets the prescribing criteria for an SGLT2 inhibitor shown to slow kidney disease progression.
  • Cardiovascular Risk: When an eligible patient may benefit from a medication with demonstrated cardiovascular outcome benefits.
  • Combination Diabetes Treatment: When an SGLT2 inhibitor is appropriate alongside metformin, a GLP-1 receptor agonist, or another diabetes medication.

GLP-1 vs. SGLT2 Inhibitors: Side-by-Side Comparison

GLP-1 receptor agonists and SGLT2 inhibitors both improve blood sugar control in patients with type 2 diabetes, but their greatest additional benefits differ. GLP-1 medications generally produce greater weight loss, while SGLT2 inhibitors have particularly strong evidence for reducing heart failure hospitalization and slowing chronic kidney disease progression. Treatment selection depends on the specific medication, medical indications, individual risk factors, and treatment goals.

ComparisonGLP-1 MedicationsSGLT2 Inhibitors
Medication CategoryGLP-1 receptor agonists, a class of medications that mimic the effects of glucagon-like peptide-1.Sodium-glucose cotransporter-2 inhibitors, a class of medications that reduce glucose reabsorption in the kidneys.
Common Medications and Brands
  • Semaglutide: Ozempic, Wegovy, and certain oral semaglutide products.
  • Liraglutide: Victoza and Saxenda.
  • Dulaglutide: Trulicity.
  • Related Medication: Tirzepatide (Mounjaro and Zepbound) activates both GIP and GLP-1 receptors.
  • Empagliflozin: Jardiance.
  • Dapagliflozin: Farxiga.
  • Canagliflozin: Invokana.
  • Ertugliflozin: Steglatro.
ManufacturerMultiple pharmaceutical manufacturers, including Novo Nordisk and Eli Lilly, depending on the medication.Multiple pharmaceutical manufacturers, including Boehringer Ingelheim, Eli Lilly, AstraZeneca, Janssen, and Merck, depending on the medication and market.
Pricing
  • Brand-Name Costs: Many GLP-1 medications have high retail prices, potentially reaching several hundred dollars or more per month without insurance.
  • Manufacturer Programs: Savings programs and self-pay offers may reduce costs for eligible patients.
  • Out-of-Pocket Expenses: Depend on the specific medication, dosage, pharmacy, insurance coverage, and available discounts.
  • Brand-Name Costs: Many SGLT2 inhibitors also have high retail prices, potentially costing several hundred dollars per month without insurance.
  • Generic Availability: Varies by medication and market, potentially affecting affordability.
  • Out-of-Pocket Expenses: Depend on the prescribed drug, pharmacy, insurance coverage, and manufacturer savings eligibility.
Insurance Coverage
  • Type 2 Diabetes: Many plans cover certain GLP-1 medications for eligible patients.
  • Weight Management: Coverage varies considerably by medication, indication, and insurance plan.
  • Prior Authorization: May require documentation of diagnosis, medical necessity, or previous treatments.
  • Type 2 Diabetes: Many insurance plans cover certain SGLT2 inhibitors for eligible patients.
  • Heart Failure and Kidney Disease: Coverage may be available for approved indications even without a diabetes diagnosis.
  • Prior Authorization: Some plans require medical documentation or preferred-drug criteria.
Main PurposeImprove blood sugar control in type 2 diabetes or support chronic weight management, depending on the specific medication and its approved indications.Improve blood sugar control in type 2 diabetes and, for certain medications, reduce risks associated with heart failure or chronic kidney disease.
Secondary Purposes
  • Cardiovascular Protection: Certain medications reduce major cardiovascular events in specified patient populations.
  • Kidney Protection: Certain GLP-1 medications have demonstrated kidney-related benefits in eligible patients.
  • Weight Management: Specific GLP-1 medications are approved for long-term weight reduction and maintenance.
  • Heart Failure: Certain SGLT2 inhibitors reduce heart failure hospitalization and other specified risks.
  • Kidney Protection: Certain medications slow chronic kidney disease progression in eligible patients.
  • Blood Pressure and Weight: May produce modest reductions in blood pressure and body weight.
How It Works
  • Insulin Secretion: Stimulates glucose-dependent insulin release.
  • Glucagon Regulation: Reduces inappropriate glucagon secretion.
  • Appetite Regulation: Acts on pathways involved in hunger and fullness.
  • Gastric Emptying: Slows stomach emptying to varying degrees.
  • Kidney Glucose Reabsorption: Blocks SGLT2 proteins in the kidneys.
  • Urinary Glucose Excretion: Increases the amount of glucose eliminated through urine.
  • Fluid and Sodium Handling: Alters kidney handling of sodium and fluid, contributing to certain cardiovascular and kidney effects.
Blood Sugar ControlGLP-1 medications can produce substantial HbA1c reductions in patients with type 2 diabetes. Effectiveness varies by medication, dosage, baseline HbA1c, and treatment duration.SGLT2 inhibitors commonly reduce HbA1c by approximately 0.5–1 percentage point in patients with type 2 diabetes, although the response varies with baseline glucose levels, kidney function, and the specific medication.
Weight Loss PotentialGLP-1 medications generally produce greater weight loss than SGLT2 inhibitors. Certain obesity-approved GLP-1 medications have produced average body-weight reductions exceeding 10% in major clinical trials, depending on the medication, dose, and study population.SGLT2 inhibitors generally produce modest weight loss, often approximately 2–3 kg in patients with type 2 diabetes. They are not FDA-approved specifically for weight management.
Appetite SuppressionMany GLP-1 medications directly affect appetite-regulating pathways, reducing hunger, increasing fullness, and decreasing food intake.SGLT2 inhibitors do not directly suppress appetite. Weight loss occurs primarily through urinary glucose and calorie loss, and compensatory increases in appetite may limit the effect.
Cardiovascular BenefitsCertain GLP-1 medications reduce major cardiovascular events, including heart attack or stroke, in specified patient populations. Benefits vary by medication and approved indication.Certain SGLT2 inhibitors reduce heart failure hospitalization and other cardiovascular risks. Some also reduce major cardiovascular events in eligible patients with type 2 diabetes and established cardiovascular disease.
Heart Failure BenefitsGLP-1 receptor agonists are not generally the preferred medication class specifically for reducing heart failure hospitalization, although individual medications may offer benefits in selected heart failure populations.SGLT2 inhibitors have strong evidence for reducing heart failure hospitalization and improving certain clinical outcomes in eligible patients with heart failure, including some without diabetes.
Kidney HealthCertain GLP-1 medications reduce kidney-related risks in specified patients with type 2 diabetes and chronic kidney disease. Benefits and approved indications vary by drug.Certain SGLT2 inhibitors slow chronic kidney disease progression and reduce kidney-related complications in eligible patients, including some without diabetes.
Blood Pressure EffectsGLP-1 medications may produce modest blood pressure reductions, particularly alongside weight loss.SGLT2 inhibitors may modestly lower blood pressure through their effects on urinary glucose, sodium, and fluid excretion.
Administration
  • Weekly Injections: Several GLP-1 medications are administered by subcutaneous injection once weekly.
  • Daily Injections: Certain GLP-1 medications require daily injections.
  • Oral Options: Oral semaglutide formulations are available with specific administration requirements.
  • Oral Tablets: SGLT2 inhibitors are generally taken by mouth once daily.
  • Administration Schedule: Timing and food requirements depend on the prescribed medication.
  • Injections: Not required for standard SGLT2 inhibitor treatment.
Dosing Considerations
  • Starting Dose: Depends on the specific GLP-1 medication.
  • Dose Escalation: Many treatments require gradual increases to improve gastrointestinal tolerability.
  • Maintenance Dose: Selected according to treatment indication, response, and tolerability.
  • Starting Dose: Depends on the prescribed SGLT2 inhibitor and treatment indication.
  • Kidney Function: Eligibility, initiation thresholds, and glucose-lowering effectiveness depend partly on eGFR.
  • Dose Adjustment: Some medications allow dose increases for additional glucose control, while others use a fixed dose for specific indications.
Potential Side Effects
  • Digestive Symptoms: Nausea, vomiting, diarrhea, constipation, and abdominal discomfort.
  • Appetite Changes: Reduced hunger and early fullness.
  • Injection-Site Reactions: Possible with injectable formulations.
  • Timing: Gastrointestinal symptoms frequently occur when beginning treatment or increasing dosage.
  • Genital Yeast Infections: Increased risk due to glucose in urine.
  • Increased Urination: More frequent urination may occur.
  • Thirst and Dizziness: Possible from fluid loss and reduced blood pressure.
  • Urinary Tract Infections: May occur, including rare serious infections.
Potential Health Risks
  • Pancreatitis: Potential acute pancreatic inflammation.
  • Gallbladder Problems: Including gallstones and gallbladder inflammation.
  • Kidney Injury: Possible dehydration-related acute kidney injury.
  • Thyroid Warning: Several GLP-1 medications carry a boxed warning concerning thyroid C-cell tumors observed in rodents.
  • Diabetic Ketoacidosis: Potentially serious ketoacidosis that can occur even without markedly elevated blood glucose.
  • Volume Depletion: Dehydration and low blood pressure, particularly in susceptible patients.
  • Serious Infections: Rare severe urinary infections or necrotizing infections of the perineum.
  • Medication-Specific Risks: Certain additional warnings, including amputation-related concerns, vary by drug.
Hypoglycemia RiskGenerally low when used alone, but the risk increases when combined with insulin or sulfonylureas.Generally low when used alone, but the risk increases when combined with insulin or sulfonylureas.
Who May Benefit Most?Eligible patients with type 2 diabetes who need improved blood sugar control and weight reduction, particularly those who may benefit from a specific medication’s cardiovascular or kidney protection. Certain GLP-1 medications also benefit eligible patients with obesity without diabetes.Eligible patients with type 2 diabetes, heart failure, or chronic kidney disease who may benefit from the medication’s glucose-lowering, cardiovascular, or kidney-protective effects. Some SGLT2 inhibitors are appropriate for qualifying patients without diabetes.
How Fast Does It Work?
  • Blood Sugar: Improvements may begin within the first weeks.
  • HbA1c: Treatment effectiveness is commonly evaluated after approximately three months.
  • Weight Loss: Develops gradually over several months, with results depending on medication, dose, and treatment duration.
  • Urinary Glucose Excretion: Begins soon after treatment starts.
  • Blood Sugar: Improvements may begin within days, with HbA1c commonly reassessed after approximately three months.
  • Weight Loss: Modest reductions generally develop over several weeks to months.
Can They Be Taken Together?Yes. A GLP-1 receptor agonist may be prescribed alongside an SGLT2 inhibitor when the combination is clinically appropriate for blood sugar control or other treatment goals.Yes. An SGLT2 inhibitor may be combined with a GLP-1 receptor agonist to address complementary metabolic, cardiovascular, or kidney-related treatment needs.

Information Accuracy Disclaimer: Medication pricing, insurance coverage, availability, approved indications, and treatment recommendations may change over time. This comparison reflects general clinical information as of November 11, 2026. 

GLP-1 receptor agonists and SGLT2 inhibitors are medication classes rather than individual drugs, and their effectiveness, approved uses, dosing requirements, and safety warnings vary by medication.

Pricing descriptions are general estimates, not verified pharmacy quotes. Patients should consult their healthcare provider, pharmacist, and insurance company for current medication-specific information.

Important Safety Information: Several GLP-1 receptor agonists carry an FDA boxed warning concerning thyroid C-cell tumors observed in rodents. Medications carrying this warning are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2). Whether these medications cause thyroid C-cell tumors in humans is unknown. 

SGLT2 inhibitors can increase the risk of ketoacidosis, genital fungal infections, and volume depletion. Ketoacidosis may occur even when blood glucose is not markedly elevated. SGLT2 inhibitors are not approved for glycemic control in patients with type 1 diabetes. Treatment selection requires individualized evaluation of medical history, kidney function, contraindications, and potential drug interactions.

Clinical Evidence: The American College of Physicians recommends adding either an SGLT2 inhibitor or a GLP-1 receptor agonist to metformin and lifestyle interventions in adults with type 2 diabetes and inadequate glycemic control. 

Its 2024 guideline identifies SGLT2 inhibitors as an option for reducing all-cause mortality, major adverse cardiovascular events, chronic kidney disease progression, and hospitalization for congestive heart failure. GLP-1 receptor agonists are recommended as an option for reducing all-cause mortality, major adverse cardiovascular events, and stroke. 

These findings support selecting treatment according to each patient’s cardiovascular, kidney, and metabolic risk profile rather than assuming one medication class is universally superior.

Sources:

Medical Disclaimer: This article is intended for informational and educational purposes only and provides a general comparison of GLP-1 receptor agonists and SGLT2 inhibitors. It is not a substitute for professional medical advice, diagnosis, or treatment. 

Medication effectiveness, safety, and suitability depend on individual medical history, health conditions, kidney function, treatment goals, and other medications. Consult a qualified healthcare professional before starting, changing, combining, or discontinuing diabetes, heart failure, kidney disease, or weight-management medications.